Targeting p27^Kip1 protein: its relevance in the therapy of human cancer

Bibliography

• Polyak K, Lee MH, Erdjument-Bromage H, Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 1994;15:59-66
   Google Scholar
• Toyoshima H, Hunter T. p27, a novel inhibitor of G1 cyclin-cdk protein kinase activity, is related to p21. Cell 1994;78:67-74
   PubMed Web of Science ®Google Scholar
• Slingerland J, Hengst L, Pan C, A novel inhibitor of cyclin-Cdk activity detected in transforming growth factor-beta-arrested epithelial cells. Mol Cell Biol 1994;14:3683-94
   PubMed Web of Science ®Google Scholar
• el-Deiry WS, Tokino T, Velculescu VE, WAF1, a potential mediator of p53 tumor suppression. Cell 1993;75:817-25
   PubMed Web of Science ®Google Scholar
• Harper JW, Adami GR, Wei N, The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 1993;75:805-16
   PubMed Web of Science ®Google Scholar
• Lee MH, Reynisdottir I, Massague J. Cloning of p57KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution. Genes Dev 1995;9:639-49
   PubMed Web of Science ®Google Scholar
• Sherr CJ, Roberts JM. Cdk inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 1999;13:1501-12
   PubMed Web of Science ®Google Scholar
• Lacy ER, Filippov I, Lewi WS, p27 binds cyclin–CDK complexes through a sequential mechanism involving binding-induced protein folding. Nat Struct Mol Biol 2004;11:358-64
   PubMed Web of Science ®Google Scholar
• Lacy ER, Wang Y, Post J, Molecular basis for the specificity of p27 toward cyclin-dependent kinases that regulate cell division. J Mol Biol 2005;349:764-73
   PubMedGoogle Scholar
• Sivakolundu SG, Bashford D, Kriwacki RW. Disordered p27Kip1 exhibits intrinsic structure resembling the Cdk2/Cyclin A-bound conformation. J Mol Biol 2005;353:1118-28
   PubMed Web of Science ®Google Scholar
• Wright PE, Dyson HJ. Intrinsically unstructured proteins: re-assessing the protein structure-function paradigm. J Mol Biol 1999;293:321-31
   PubMed Web of Science ®Google Scholar
• Flaugh SL, Lumb KJ. Effects of macromolecular crowding on the intrinsically disordered proteins c-Fos and p27Kip1. Biomacromolecules 2001;2:538-40
   PubMedGoogle Scholar
• Borriello A, Cucciolla V, Oliva A, p27Kip1 metabolism: a fascinating labyrinth. Cell Cycle 2007;9:1053-61
   Google Scholar
• Besson A, Gurian-West M, Schmidt A, p27Kip1 modulates cell migration through the regulation of RhoA activation. Genes Dev 2004;15:862-76
   Google Scholar
• Baldassarre G, Belletti B, Nicoloso MS, p27Kip1-stathmin interaction influences sarcoma cell migration and invasion. Cancer Cell 2005;7:51-63
   PubMed Web of Science ®Google Scholar
• Sugiyama Y, Tomoda K, Tanaka T, Direct binding of the signal-transducing adaptor Grb2 facilitates down-regulation of the cyclin-dependent kinase inhibitor p27Kip1. J Biol Chem 2001;276:12084-90
   PubMed Web of Science ®Google Scholar
• Fujita N, Sato S, Katayama K, Tsuruo T. Akt-dependent phosphorylation of p27Kip1 promotes binding to 14-3-3 and cytoplasmic localization. J Biol Chem 2002;277:28706-13
   PubMedGoogle Scholar
• Sekimoto T, Fukumoto M, Yoneda Y. 14-3-3 suppresses the nuclear localization of threonine 157-phosphorylated p27. EMBO J 2004;23:1934-42
   PubMedGoogle Scholar
• Connor MK, Kotchetkov R, Cariou S, CRM1/Ran-mediated nuclear export of p27Kip1 involves a nuclear export signal and links p27 export and proteolysis. Mol Biol Cell 2003;14:201-13
   PubMed Web of Science ®Google Scholar
• Polyak K, Kato JY, Solomon MJ, p27kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest. Genes Dev 1994;8:9-22
   PubMed Web of Science ®Google Scholar
• Qian X, Jin L, Grande JP, Lloyd RV. Transforming growth factor-beta and p27 expression in pituitary cells. Endocrinology 1996;137:3051-60
   PubMedGoogle Scholar
• Sa G, Guo Y, Stacey DW. The regulation of S phase initiation by p27Kip1 in NIH3T3 cells. Cell Cycle 2005;4:618-27
   PubMedGoogle Scholar
• Hitomi M, Yang K, Guo Y, p27Kip1 and cyclin dependent kinase 2 regulate passage through the restriction point. Cell Cycle 2006;5:2281-9
   PubMed Web of Science ®Google Scholar
• Ji P, Zhu L. Using kinetic studies to uncover new Rb functions in inhibiting cell cycle progression. Cell Cycle 2005;4:373-5
   PubMed Web of Science ®Google Scholar
• Larrea MD, Liang J, Da Silva T, Phosphorylation of p27Kip1 regulates assembly and activation of cyclin D1-Cdk4. Mol Cell Biol 2008;28:6462-72
   PubMed Web of Science ®Google Scholar
• Fero ML, Rivkin M, Tasch M, A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27(Kip1)-deficient mice. Cell 1996;85:733-44
   PubMed Web of Science ®Google Scholar
• Kiyokawa H, Kineman RD, Manova-Todorova KO, Enhanced growth of mice lacking the cyclin-dependent kinase inhibitor function of p27Kip1. Cell 1996;85:721-32
   PubMed Web of Science ®Google Scholar
• Nakayama K, Ishida N, Shirane M, Mice lacking p27Kip1 display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell 1996;85:707-20
   PubMed Web of Science ®Google Scholar
• Aleem E, Kiyokawa H, Kaldis P. Cdc2-cyclin E complexes regulate the G1/S phase transition. Nat Cell Biol 2005;7:831-6
   PubMed Web of Science ®Google Scholar
• Fero M, Randel E, Gurley K, The murine gene p27Kip1 is haplo-insufficient for tumour suppression. Nature 1998;396:177-80
   PubMed Web of Science ®Google Scholar
• Molatore S, Kiermaier E, Jung C, Characterization of a naturally-occurring p27 mutation predisposing to multiple endocrine tumors. Mol Cancer 2010;9:116
   Google Scholar
• Nguyen L, Besson A, Heng JI, p27kip1 independently promotes neuronal differentiation and migration in the cerebral cortex. Genes Dev 2006;20:1511-24
   PubMed Web of Science ®Google Scholar
• Larrea MD, Hong F, Wander SA, RSK1 drives p27Kip1 phosphorylation at T198 to promote RhoA inhibition and increase cell motility. Proc Natl Acad Sci USA 2009;106:9268-73
   PubMed Web of Science ®Google Scholar
• McAllister SS, Becker-Hapak M, Pintucci G, Novel p27kip1 C-terminal scatter domain mediates Rac-dependent cell migration independent of cell cycle arrest functions. Mol Cell Biol 2003;23:216-28
   PubMed Web of Science ®Google Scholar
• Nagahara H, Vocero-Akbani AM, Snyder EL, Transduction of full-length TAT fusion proteins into mammalian cells: TAT- p27Kip1 induces cell migration. Nat Med 1998;4:1449-52
   PubMed Web of Science ®Google Scholar
• Wu FY, Wang SE, Sanders ME, Reduction of cytosolic p27Kip1 inhibits cancer cell motility, survival, and tumorigenicity. Cancer Res 2006;66:2162-72
   PubMed Web of Science ®Google Scholar
• Denicourt C, Saenz CC, Datnow B, Relocalized p27Kip1 tumor suppressor functions as a cytoplasmic metastatic oncogene in melanoma. Cancer Res 2007;67:9238-43
   PubMed Web of Science ®Google Scholar
• Goukassian D, Diez-Juan A, Asahara T, Overexpression of p27Kip1 by doxycycline-regulated adenoviral vectors inhibits endothelial cell proliferation and migration and impairs angiogenesis. FASEB J 2001;11:1877-85
   Google Scholar
• Sun J, Marx SO, Chen HJ, Role for p27Kip1 in vascular smooth muscle cell migration. Circulation 2001;103:2967-72
   PubMed Web of Science ®Google Scholar
• Diez-Juan A, Andres V. Coordinate control of proliferation and migration by the p27Kip1cyclin-dependent kinase/Retinoblastoma pathway in vascular smooth muscle cells and fibroblasts. Circ Res 2003;92:402-10
   PubMedGoogle Scholar
• Supriatno, Harada K, Kawaguchi S, Effect of p27Kip1 on the ability of invasion and metastasis of an oral cancer cell line. Oncol Rep 2003;10:527-32
   PubMedGoogle Scholar
• Nguyen L, Besson A, Roberts JM, Guillemot F. Coupling cell cycle exit, neuronal differentiation and migration in cortical neurogenesis. Cell Cycle 2006;5:2314-18
   PubMed Web of Science ®Google Scholar
• Schiappacassi M, Lovat F, Canzonieri V, p27Kip1 expression inhibits glioblastoma growth, invasion, and tumor-induced neoangiogenesis. Mol Canc Ther 2008;7:1164-75
   PubMed Web of Science ®Google Scholar
• Belletti B, Pellizzari I, Berton S, p27kip1 controls cell morphology and motility by regulating microtubule-dependent lipid raft recycling. Mol Cell Biol 2010;30:2229-40
   PubMedGoogle Scholar
• Katayose Y, Kim M, Rakkar AN, Promoting apoptosis: a novel activity associated with the cyclin-dependent kinase inhibitor p27. Cancer Res 1997;57:5441-5
   PubMed Web of Science ®Google Scholar
• An B, Goldfarb RH, Siman R, Dou QP. Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts. Cell Death Differ 1998;12:1062-75
   Google Scholar
• Drexler HCA. The role of l. p27Kip1 in proteasome inhibitor induced apoptosis. Cell Cycle 2003;2:438-41
   PubMedGoogle Scholar
• Nickeleit I, Zender S, Sasse F, Argyrin a reveals a critical role for the tumor suppressor protein p27kip1 in mediating antitumor activities in response to proteasome inhibition. Cancer Cell 2008;14:23-35
   PubMed Web of Science ®Google Scholar
• Hiromura K, Pippin JW, Fero ML, Modulation of apoptosis by the cyclin-dependent kinase inhibitor p27Kip1. J Clin Invest 1999;103:597-604
   PubMedGoogle Scholar
• Dimanche-Boitrel M, Micheau O, Hammann A, Contribution of the cyclin-dependent kinase inhibitor p27KIP1 to the confluence-dependent resistance of colon carcinoma HT29 cells. Int J Cancer 1998;77:796-802
   PubMedGoogle Scholar
• Yang Q, Sakurai T, Yoshimura, Overexpression of p27 protein in human breast cancer correlates with in vitro resistance to doxorubicin and mitomycin C. Anticancer Res 2000;20:4319-22
   PubMedGoogle Scholar
• Le TVT, Seo Y, Ryu CJ, Increased expression of p27 is associated with the cisplatin resistance in gastric cancer cell line YCC-3. Arch Pharm Res 2010;33:1127-32
   PubMed Web of Science ®Google Scholar
• Levkau B, Koyama H, Raines EW, Cleavage of p21Cip1/Waf1 and p27Kip1 mediates apoptosis in endothelial cells through activation of Cdk2: role of a caspase cascade. Mol Cell 1998;4:553-63
   Google Scholar
• Liang J, Shao SH, Xu ZX, The energy sensing LKB1-AMPK pathway regulates p27Kip1 phosphorylation mediating the decision to enter autophagy or apoptosis. Nat Cell Biol 2007;9:218-24
   PubMed Web of Science ®Google Scholar
• Galardi S, Mercatelli N, Giorda E, miR-221 and miR-222 expression affects the proliferation potential of human prostate carcinoma cell lines by targeting p27Kip1. J Biol Chem 2007;282:23716-24
   PubMed Web of Science ®Google Scholar
• le Sage C, Nagel R, Egan DA, Regulation of the p27Kip1 tumor suppressor by miR-221 and miR-222 promotes cancer cell proliferation. EMBO J 2007;26:3699-708
   PubMed Web of Science ®Google Scholar
• Visone R, Russo L, Pallante P, MicroRNAs (miR)-221 and miR-222, both overexpressed in human thyroid papillary carcinomas, regulate p27Kip1 protein levels and cell cycle. Endocr Relat Cancer 2007;14:791-8
   PubMed Web of Science ®Google Scholar
• Fornari F, Gramantieri L, Ferracin M, MiR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma. Oncogene 2008;27:5651-61
   PubMed Web of Science ®Google Scholar
• Miller TE, Ghoshal K, Ramaswamy B, MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1. J Biol Chem 2008;283:29897-903
   PubMed Web of Science ®Google Scholar
• Fu X, Wang Q, Chen J, Clinical significance of miR-221 and its inverse correlation with p27Kip1 in hepatocellular carcinoma. Mol Biol Rep 2010: published online 10 February 2010, doi: 10.1007/s11033-010-9969-5
   Google Scholar
• Frenquelli M, Muzio M, Scielzo C, MicroRNA and proliferation control in chronic lymphocytic leukemia: functional relationship between miR-221/222 cluster and p27. Blood 2010;115:3949-59
   PubMed Web of Science ®Google Scholar
• Wurz K, Garcia RL, Goff BA, MiR-221 and MiR-222 alterations in sporadic ovarian carcinoma: relationship to CDKN1B, CDKNIC and overall survival. Genes Chromosomes Cancer 2010;49:577-84
   PubMed Web of Science ®Google Scholar
• Kedde M, van Kouwenhove M, Zwart W, A Pumilio-induced RNA structure switch in p27-3′?UTR controls miR-221 and miR-222 accessibility. Nat Cell Biol 2010;12:1014-20
   PubMed Web of Science ®Google Scholar
• Lu Z, Hunter T. Ubiquitylation and proteasomal degradation of the p21Cip1, p27Kip1 and p57Kip2 CDK inhibitors. Cell Cycle 2010;12:1-11
   Google Scholar
• Vlach J, Hennecke S, Amati B. Phosphorylation-dependent degradation of the cyclin-dependent kinase inhibitor p27. EMBO J 1997;16:5334-44
   PubMed Web of Science ®Google Scholar
• Montagnoli A, Fiore F, Eytan E, Ubiquitination of p27 is regulated by Cdk-dependent phosphorylation and trimeric complex formation. Genes Dev 1999;13:1181-9
   PubMed Web of Science ®Google Scholar
• Carrano AC, Eytan E, Hershko A, Pagano M. SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27. Nat Cell Biol 1999;1:193-9
   PubMed Web of Science ®Google Scholar
• Ganoth D, Bornstein G, Ko TK, The cell-cycle regulatory protein Cks1 is required for SCF(Skp2)-mediated ubiquitinylation of p27. Nat Cell Biol 2001;3:321-4
   PubMed Web of Science ®Google Scholar
• Zhou W, Yang Q, Low CB, Pin1 catalyzes conformational changes of Thr-187 in p27Kip1 and mediates its stability through a polyubiquitination process. J Biol Chem 2009;284:23980-8
   Google Scholar
• Denti S, Fernandez-Sanchez ME, Rogge L, Bianchi E. The COP9 signalosome regulates Skp2 levels and proliferation of human cells. J Biol Chem 2006;281:32188-96
   PubMed Web of Science ®Google Scholar
• Li B, Jia N, Kapur R, Chun KT. Cul4A targets p27 for degradation and regulates proliferation, cell cycle exit, and differentiation during erythropoiesis. Blood 2006;107:4291-9
   PubMed Web of Science ®Google Scholar
• Kamura T, Hara T, Matsumoto M, Cytoplasmic ubiquitin ligase KPC regulates proteolysis of p27Kip1 at G1 phase. Nat Cell Biol 2004;6:1229-35
   PubMed Web of Science ®Google Scholar
• Kotoshiba S, Kamura T, Hara T, Molecular dissection of the interaction between p27 and Kip1 ubiquitylation-promoting complex, the ubiquitin ligase that regulates proteolysis of p27 in G1 phase. J Biol Chem 2005;280:17694-700
   PubMed Web of Science ®Google Scholar
• Rodier G, Montagnoli A, Di Marcotullio L, p27 cytoplasmic localization is regulated by phosphorylation on Ser10 and is not a prerequisite for its proteolysis. EMBO J 2001;20:6672-82
   PubMed Web of Science ®Google Scholar
• Ishida N, Hara T, Kamura T, Phosphorylation of p27Kip1 on serine 10 is required for its binding to CRM1 and nuclear export. J Biol Chem 2002;277:14355-8
   PubMed Web of Science ®Google Scholar
• Delmas C, Aragou N, Poussard S, MAP kinase-dependent degradation of p27Kip1 by calpains in choroidal melanoma cells requirement of p27Kip1 nuclear export. J Biol Chem 2003;278:12443-51
   PubMed Web of Science ®Google Scholar
• Akashiba H, Matsuki N, Nishiyama N. Calpain activation is required for glutamate-induced p27 down-regulation in cultured cortical neurons. J Neurochem 2006;99:733-44
   PubMedGoogle Scholar
• Fuster JJ, Gonzalez JM, Edo MD, Tumor suppressor p27Kip1 undergoes endolysosomal degradation through its interaction with sorting nexin 6. FASEB J 2010;24:2998-3009
   PubMedGoogle Scholar
• Kotake Y, Nakayama K, Ishida N, Nakayama KI. Role of serine 10 phosphorylation in p27 stabilization revealed by analysis of p27 knock-in mice harboring a serine 10 mutation. J Biol Chem 2005;280:1095-102
   PubMed Web of Science ®Google Scholar
• Besson A, Gurian-West M, Chen X, Subcellular localization, and tumor suppression stability, Kip1 A pathway in quiescent cells that controls p27. Genes Dev 2006;20:47-64
   PubMed Web of Science ®Google Scholar
• Ishida N, Kitagawa M, Hatakeyama S, Nakayama K. Phosphorylation at serine 10, a major phosphorylation site of p27Kip1, increases its protein stability. J Biol Chem 2000;275:25146-54
   PubMed Web of Science ®Google Scholar
• Boehm M, Yoshimoto T, Crook MF, A growth factor-dependent nuclear kinase phosphorylates p27Kip1 and regulates cell cycle progression. EMBO J 2002;21:3390-401
   PubMed Web of Science ®Google Scholar
• Alessandrini A, Chiaur DS, Pagano M. Regulation of the cyclin-dependent kinase inhibitor p27 by degradation and phosphorylation. Leukemia 1997;11:342-5
   PubMedGoogle Scholar
• Reed SI. Focus on p27. Keeping p27Kip1 in the cytoplasm. A second front in cancer's war on p27. Cell Cycle 2002;1:389-90
   PubMed Web of Science ®Google Scholar
• Fujita N, Sato S, Tsuruo T. Phosphorylation of p27Kip1 at threonine 198 by p90 localization. J Biol Chem 2003;278:49254-60
   PubMed Web of Science ®Google Scholar
• Deng X, Mercer SE, Shah S, The cyclin-dependent kinase inhibitor p27Kip1 is stabilized in G0 by Mirk/dyrk1B kinase. J Biol Chem 2004;279:22498-504
   PubMedGoogle Scholar
• Kawauchi T, Chihama K, Nabeshima YI, Hoshino M. Cdk5 phosphorylates and stabilizes p27Kip1 contributing to actin organization and cortical neuronal migration. Nat Cell Biol 2006;8:17-26
   PubMed Web of Science ®Google Scholar
• Kajihara R, Fukushige S, Shioda N, CaMKII phosphorylates serine 10 of p27 and confers apoptosis resistance to HeLa cells. Biochem Biophys Res Commun 2010;401:350-5
   Google Scholar
• Liang J, Zubovitz J, Petrocelli T, PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest. Nat Med 2002;8:1153-60
   PubMed Web of Science ®Google Scholar
• Shin I, Yakes FM, Rojo F, PKB/Akt mediates cell-cycle progression by phosphorylation of p27Kip1 at threonine 157 and modulation of its cellular localization. Nat Med 2002;8:1145-52
   PubMed Web of Science ®Google Scholar
• Viglietto G, Motti ML, Bruni P, Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27Kip1 by PKB/Akt-mediated phosphorylation in breast cancer. Nat Med 2002;8:1136-44
   PubMed Web of Science ®Google Scholar
• Chu I, Sun J, Arnaout A, p27 phosphorylation by Src regulates inhibition of cyclin E-Cdk2. Cell 2007;128:281-94
   PubMed Web of Science ®Google Scholar
• Grimmler M, Wang Y, Mund T, Cdk-inhibitory activity and stability of p27Kip1 are directly regulated by oncogenic tyrosine kinases. Cell 2007;128:269-80
   PubMed Web of Science ®Google Scholar
• Kardinal C, Dangers M, Kardinal A, Tyrosine phosphorylation modulates binding preference to cyclin-dependent kinases and subcellular localization of p27Kip1 in the acute promyelocytic leukemia cell line NB4. Blood 2006;107:1133-40
   PubMedGoogle Scholar
• Chu IM, Hengst L, Slingerland JM. The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy. Nat Rev Cancer 2008;8:253-67
   PubMed Web of Science ®Google Scholar
• Loda M, Cukor B, Tam SW, Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat Med 1977;3:231-4
   Google Scholar
• Lu CD, Morita S, Ishibashi T, Loss of p27Kip1 expression independently predicts poor prognosis for patients with resectable pancreatic adenocarcinoma. Cancer 1999;85:1250-60
   PubMed Web of Science ®Google Scholar
• Mineta H, Miura K, Suzuki I, Low p27 expression correlates with poor prognosis for patients with oral tongue squamous cell carcinoma. Cancer 1999;85:1011-17
   PubMed Web of Science ®Google Scholar
• Migita T, Oda Y, Naito S, Tsuneyoshi M. Low expression of p27Kip1 is associated with tumor size and poor prognosis in patients with renal cell carcinoma. Cancer 2002;94:973-9
   PubMed Web of Science ®Google Scholar
• Gillies JK, Lorimer IA. Regulation of p27Kip1 by miRNA 221/222 in glioblastoma. Cell Cycle 2007;6:2005-9
   PubMed Web of Science ®Google Scholar
• Lee EJ, Gusev Y, Jiang J, Expression profiling identifies microRNA signature in pancreatic cancer. Int J Cancer 2007;120:1046-54
   PubMed Web of Science ®Google Scholar
• Hershko DD. Oncogenic properties and prognostic implications of the ubiquitin ligase Skp2 in cancer. Cancer 2008;112:1415-24
   PubMed Web of Science ®Google Scholar
• Susaki E, Nakayama K, Nakayama KI. Cyclin D2 translocates p27 out of the nucleus and promotes its degradation at the G0-G1 transition. Mol Cell Biol 2007;27:4626-40
   PubMedGoogle Scholar
• He S, Lu M, Xue W, Phosphorylated p27Kip1 on Thr157 is an important prognosis in human hepatocellular carcinoma in vivo and in vitro. Med Oncol 2010: published online 28 Janury 2010, doi: 10.1007/s12032-009-9408-4
   Google Scholar
• Kim J, Jonasch E, Alexander A, Cytoplasmic sequestration of p27 via AKT phosphorylation in renal cell carcinoma. Clin Cancer Res 2009;15:81-90
   PubMed Web of Science ®Google Scholar
• Porter PL, Barlow WE, Yeh I-T, p27Kip1 and cyclin E expression and breast cancer survival after treatment with adjuvant chemotherapy. J Natl Cancer Inst 2006;98:1723-31
   PubMed Web of Science ®Google Scholar
• Spataro VJ, Litman H, Viale G, International breast cancer study group. Decreased immunoreactivity for p27 protein in patients with early-stage breast carcinoma is correlated with HER-2/neu overexpression and with benefit from one course of perioperative chemotherapy in patients with negative lymph node status: results from international breast cancer study group trial, V. Cancer 2003;97:1591-600
   PubMedGoogle Scholar
• Sion-Vardy N, Freedman J, Lazarov I, p27kip1 Expression in non-small cell lung cancer is not an independent prognostic factor. Anticancer Res 2010;30:3699-704
   PubMedGoogle Scholar
• Liang J, Slingerland JM. Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression. Cell Cycle 2003;2:339-45
   PubMed Web of Science ®Google Scholar
• Hirsch FR, Varella-Garcia M, Bunn PA, Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 2003;21:3798-807
   PubMed Web of Science ®Google Scholar
• Lynch TJ, Bell DW, Sordella R, Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39
   PubMed Web of Science ®Google Scholar
• Ono K, Sugio K, Uramoto H, Discrimination of multiple primary lung cancers from intrapulmonary metastasis based on the expression of four cancer-related proteins. Cancer 2009;115:3489-500
   PubMedGoogle Scholar
• Bertagnolli MM, Warren RS, Niedzwiecki D, p27Kip1 in stage III colon cancer: implications for outcome following adjuvant chemotherapy in cancer and leukemia group B protocol 89803. Clin Cancer Res 2009;15:2116-22
   PubMedGoogle Scholar
• Meyerhardt JA, Ogino S, Kirkner GJ, Interaction of molecular markers and physical activity on mortality in patients with colon cancer. Clin Cancer Res 2009;15:5931-6
   PubMedGoogle Scholar
• Watson NFS, Durrant LG, John H, Cytoplasmic expression of p27Kip1 is associated with a favourable prognosis in colorectal cancer patients. World J Gastroenterol 2006;12:6299-304
   PubMedGoogle Scholar
• Manne U, Jhala NC, Jones J, Prognostic significance of p27kip1 expression in colorectal adenocarcinomas is associated with tumor stage. Clin. Cancer Res 2004;10:1743-52
   Google Scholar
• Romics I, Banfi G, Szekely E, Expression of p21waf1/cip1, p27kip1, p63 and androgen receptor in low and high gleason score prostate cancer. Pathol Oncol Res 2008;14:307-11
   PubMedGoogle Scholar
• Li R, Wheeler TM, Dai H, Biological correlates of p27 compartmental expression in prostate cancer. J Urol 2006;175:528-32
   PubMedGoogle Scholar
• Aleshin A, Finn RS. SRC: a century of science brought to the clinic. Neoplasia 2010;12:599-607
   PubMed Web of Science ®Google Scholar
• Chen Y, Guggisberg N, Jorda M, Combined Src and aromatase inhibition impairs human breast cancer growth in vivo and bypass pathways are activated in AZD0530-resistant tumors. Clinical Cancer Res 2009;15:3396-405
   PubMed Web of Science ®Google Scholar
• Andreu EJ, Lledo E, Enric Poch E, BCR-ABL induces the expression of Skp2 through the PI3K pathway to promote p27Kip1 degradation and proliferation of chronic myelogenous leukemia cells. Cancer Res 2005;65:3264-72
   PubMed Web of Science ®Google Scholar
• Liu Y, Perdreau SA, Chatterjee P, Imatinib mesylate induces quiescence in gastrointestinal stromal tumor cells through the CDH1-SKP2- p27Kip1 signaling axis. Cancer Res 2008;68:9015-23
   PubMedGoogle Scholar
• Marks PA, Rifkind RA, Richon VM, Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 2001;1:194-202
   PubMed Web of Science ®Google Scholar
• Walkinshaw DR, Yang XJ. Histone deacetylase inhibitors as novel anticancer therapeutics. Curr Oncol 2008;15:237-43
   PubMed Web of Science ®Google Scholar
• Chen JS, Faller DV. Histone deacetylase inhibition-mediated post-translational elevation of p27KIP1 protein levels is required for G1 arrest in fibroblasts. J Cell Physiol 2005;202:87-99
   PubMedGoogle Scholar
• Borriello A, Della Pietra V, Criscuolo M, p27Kip1 accumulation is associated with retinoic-induced neuroblastoma differentiation: evidence of a decreased proteasome-dependent degradation. Oncogene 2000;19:51-60
   PubMed Web of Science ®Google Scholar
• Borriello A, Cucciolla V, Criscuolo M, Retinoic acid induces p27Kip1 nuclear accumulation by modulating its phosphorylation. Cancer Res 2006;66:4240-8
   Google Scholar
• Oliva A, Borriello A, Zeppetelli S, Retinoic acid inhibits the growth of bone marrow mesenchymal stem cells and induces p27Kip1 and p16INK4A up-regulation. Mol Cell Biochem 2003;247:55-60
   PubMedGoogle Scholar
• Orlowski RZ, Kuhn DJ. Proteasome inhibitors in cancer therapy: lessons from the first decade. Clin Cancer Res 2008;14:1649-57
   PubMed Web of Science ®Google Scholar
• Baiz D, Pozzato G, Dapas B, Bortezomib arrests the proliferation of hepatocellular carcinoma cells HepG2 and JHH6 by differentially affecting E2F1, p21 and p27 levels. Biochimie 2009;91:373-82
   PubMed Web of Science ®Google Scholar
• Timmerbeul I, Garrett-Engele CM, Kossatz U, Testing the importance of p27 degradation by the SCFskp2 pathway in murine models of lung and colon cancer. Proc Natl Acad Sci USA 2006;103:14009-14
   PubMedGoogle Scholar